In addition, after treating breast cancer with exemestane, the polymorphism of the UGT2B17 gene leads to individual differences in the drug and the upregulation of UGT2B17 expression in some patients may be related to the development of drug resistance (78). This evidence concerns the gene UGT2B17 and breast carcinoma.